SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2005 / Cilt: 5 - Sayı: 2

Thrombotic, fibrinolytic and proliferative activities of pulmonary vascular bed in secondary pulmonary hypertension

Sekonder pulmoner hipertansiyonda pulmoner vasküler yatağın trombotik, fibrinolitik ve proliferatif aktiviteleri

Yücel BALBAY
Selime AYAZ
Öner A. BALBAY
Kumral ERGÜN
Gökhan CİHAN
Filiz BİLGİÇ
Hatice ŞAŞMAZ
Dursun ARAS
Kerim ÇAĞLI
Şule KORKMAZ
Pages
95–100
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Although mean level of VEGF in LV and PA were found to be in normal range, it was significantly higher in LV than in PA (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To determine whether pulmonary vascular bed contributes to the development of in situ thrombosis and vascular remodelling in secondary pulmonary hypertension (SPH) via changes in its local secretory activities.
📊
Key Findings & Data:Methods: Seventy-one patients with the diagnosis of secondary pulmonary hypertension (38 females, mean age 40.36± 1.05 years) were included in the study.
💡
Conclusion & Impact:Results: Although mean level of VEGF in LV and PA were found to be in normal range, it was significantly higher in LV than in PA (p
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To determine whether pulmonary vascular bed contributes to the development of in situ thrombosis and vascular remodelling in secondary pulmonary hypertension (SPH) via changes in its local secretory activities. Methods: Seventy-one patients with the diagnosis of secondary pulmonary hypertension (38 females, mean age 40.36± 1.05 years) were included in the study. Selective right and left heart catheterization was performed to each patient for diagnostic purposes. Blood samples obtained from left ventricle (LV) and pulmonary artery (PA) of each patient were analyzed for levels of plasminogen activator inhibitor-1 (PAI-1), platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), D-dimer, von Willebrand factor (vWF), protein-C, antithrombin-III, fibrinogen, and plasminogen. Results were compared between LV and PA. Correlation analysis between each parameter and mean pulmonary artery pressure (MPAP) was performed. Results: Although mean level of VEGF in LV and PA were found to be in normal range, it was significantly higher in LV than in PA (p

Özet

Amaç: Bu çalışma, sekonder pulmoner hipertansiyonda (SPH) sıklıkla izlenen in situ tromboz gelişimine ve vasküler yeniden biçimlenmeye pulmoner vasküler yatağın lokal katkısını araştırmak için planlanmıştır. Yöntemler: Kliniğimizde kalp kateterizasyonu yapılan 71 SPH hastası (38 kadın, 33 erkek; yaş ortalaması 40.36± 1.05 yıl) çalışmaya dahil edilmiştir. Her hastanın pulmoner arter (PA) ve sol ventrikülünden (LV) alınan kan örneklerinde plazminojen aktivator inhibitör-1 (PAI-1), trombosit kökenli büyüme faktörü (PDGF), damar endoteli büyüme faktörü (VEGF), D-Dimer, von-Willebrand faktörü (vWF), protein-C, antitrombin-III, fibrinojen ve plazminojen düzeyleri bakılarak karşılaştırılmıştır. Ayrıca her parametrenin ortalama PA basıncı (MPAP) ile korelasyonu araştırılmıştır. Bulgular: Ortalama VEGF düzeyi LV’de PA’e göre daha yüksektir (p

🔖

Cite This Article

BALBAY, Y., AYAZ, S., BALBAY, Ö. A., ERGÜN, K., CİHAN, G., BİLGİÇ, F., ŞAŞMAZ, H., ARAS, D., ÇAĞLI, K., KORKMAZ, Ş. (2022). Thrombotic, fibrinolytic and proliferative activities of pulmonary vascular bed in secondary pulmonary hypertension. Anadolu Kardiyoloji Dergisi, Cilt: 5 - Sayı: 2, 95–100. https://ajindex.com/articles/437433

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Rich S, McLaughlin VV. Pulmonary hypertension. In: Zipes DP, Libby P, Bonow RO, Braunwald E, editors. 7th ed. Braunwald’s Heart Disease. A Textbook of Cardiovascular Medicine. Philadelphia: Elsevier Saunders; 2005. p. 1808-16
  2. Welsh CH, Hassell KL, Badesh DB, Kressin DC, Marlar RA. Coagulation and fibrinoliytic profiles in patients with severe pulmonary hypertension. Chest 1996; 110: 710-7
  3. Herve P, Humbert M, Sitbon O, et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001; 22: 451-8
  4. Wagenvoort CA, Mulder GH. Thrombotic lesions in primary plexogenic arteriopathy. Chest 1993; 103: 844-9
  5. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and importance of thrombosis. Circulation 1984; 70: 580-7
  6. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81
  7. Sakamaki F, Kyotani S, Nagaya N, et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000; 102: 2720-5
  8. Yock PG, Popp RL. Non-invasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70: 657-62
  9. Isobe M, Yazaki Y, Takaku F, et al. Prediction of pulmonary artery pressure in adults by pulsed Doppler echocardiography. Am J Cardiol 1986; 57: 316-21
  10. Chassagne C, Eddahibi S, Adamy C, et al. Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension. Am J Respir Cell Mol Biol 2000; 22: 323-32
  11. Umut S, Erdinç E. Toraks Kitapları. Kronik Obstrüktif Akciğer Hastalı ğı.İstanbul; Toraks Derneği. 2000
  12. Kruger S, Hoffman R, Skobel E, et al. Impairment of ventilatory parameters and exercise capacity in patients with pulmonary hypertension and chronic heart insufficiency. Dtsch Med Wochenschr 2002;127: 839-44
  13. Preisner KT. Anticoagulant potential of endothelial cell membrane components. Hemostasis 1988; 18: 271-306
  14. Hooper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 1998; 12: 1446-9
  15. Hassel KL. Altered hemostasis in pulmonary hypertension. Blood Coagul Fibrinolysis 1998; 9: 107-17
  16. Moraes D, Loscalzo J. Pulmonary hypertension: newer concepts in diagnosis and